164 related articles for article (PubMed ID: 34726055)
1. A Perspective on Medicinal Chemistry Approaches for Targeting Pyruvate Kinase M2.
Arora S; Joshi G; Chaturvedi A; Heuser M; Patil S; Kumar R
J Med Chem; 2022 Jan; 65(2):1171-1205. PubMed ID: 34726055
[TBL] [Abstract][Full Text] [Related]
2. Biochemical and structural insights into how amino acids regulate pyruvate kinase muscle isoform 2.
Nandi S; Dey M
J Biol Chem; 2020 Apr; 295(16):5390-5403. PubMed ID: 32144209
[TBL] [Abstract][Full Text] [Related]
3. Pyruvate kinase M2: A simple molecule with complex functions.
Alquraishi M; Puckett DL; Alani DS; Humidat AS; Frankel VD; Donohoe DR; Whelan J; Bettaieb A
Free Radic Biol Med; 2019 Nov; 143():176-192. PubMed ID: 31401304
[TBL] [Abstract][Full Text] [Related]
4. The cysteine residue at 424th of pyruvate kinase M2 is crucial for tetramerization and responsiveness to oxidative stress.
Masaki S; Hashimoto K; Kihara D; Tsuzuki C; Kataoka N; Suzuki K
Biochem Biophys Res Commun; 2020 Jun; 526(4):973-977. PubMed ID: 32295714
[TBL] [Abstract][Full Text] [Related]
5. The Role of PKM2 in Metabolic Reprogramming: Insights into the Regulatory Roles of Non-Coding RNAs.
Puckett DL; Alquraishi M; Chowanadisai W; Bettaieb A
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33503959
[TBL] [Abstract][Full Text] [Related]
6. PKM2-dependent glycolysis promotes the proliferation and migration of vascular smooth muscle cells during atherosclerosis.
Zhao X; Tan F; Cao X; Cao Z; Li B; Shen Z; Tian Y
Acta Biochim Biophys Sin (Shanghai); 2020 Jan; 52(1):9-17. PubMed ID: 31867609
[TBL] [Abstract][Full Text] [Related]
7. Glycolytic reprogramming in cancer cells: PKM2 dimer predominance induced by pulsatile PFK-1 activity.
Shi X; You L; Luo RY
Phys Biol; 2019 Sep; 16(6):066007. PubMed ID: 31469100
[TBL] [Abstract][Full Text] [Related]
8. Structural basis for allosteric regulation of pyruvate kinase M2 by phosphorylation and acetylation.
Nandi S; Razzaghi M; Srivastava D; Dey M
J Biol Chem; 2020 Dec; 295(51):17425-17440. PubMed ID: 33453989
[TBL] [Abstract][Full Text] [Related]
9. Allosteric regulation of PKM2 allows cellular adaptation to different physiological states.
Gui DY; Lewis CA; Vander Heiden MG
Sci Signal; 2013 Feb; 6(263):pe7. PubMed ID: 23423437
[TBL] [Abstract][Full Text] [Related]
10. Recent Advances on PKM2 Inhibitors and Activators in Cancer Applications.
Chen P; Lou L; Sharma B; Li M; Xie C; Yang F; Wu Y; Xiao Q; Gao L
Curr Med Chem; 2024; 31(20):2955-2973. PubMed ID: 37455458
[TBL] [Abstract][Full Text] [Related]
11. Tumor M2-PK: A novel urine marker of bladder cancer.
Liu W; Woolbright BL; Pirani K; Didde R; Abbott E; Kaushik G; Martin P; Hamilton-Reeves J; Taylor JA; Holzbeierlein JM; Anant S; Lee EK
PLoS One; 2019; 14(6):e0218737. PubMed ID: 31246990
[TBL] [Abstract][Full Text] [Related]
12. Vitamin K(3) and K(5) are inhibitors of tumor pyruvate kinase M2.
Chen J; Jiang Z; Wang B; Wang Y; Hu X
Cancer Lett; 2012 Mar; 316(2):204-10. PubMed ID: 22154083
[TBL] [Abstract][Full Text] [Related]
13. Discovery of boronic acid-based potent activators of tumor pyruvate kinase M2 and development of gastroretentive nanoformulation for oral dosing.
Patle R; Shinde S; Patel S; Maheshwari R; Jariyal H; Srivastava A; Chauhan N; Globisch C; Jain A; Tekade RK; Shard A
Bioorg Med Chem Lett; 2021 Jun; 42():128062. PubMed ID: 33901643
[TBL] [Abstract][Full Text] [Related]
14. Mechanistic and Structural Insights into Cysteine-Mediated Inhibition of Pyruvate Kinase Muscle Isoform 2.
Srivastava D; Nandi S; Dey M
Biochemistry; 2019 Sep; 58(35):3669-3682. PubMed ID: 31386812
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of novel sulfonamide derivatives containing pyridin-3-ylmethyl 4-(benzoyl)piperazine-1-carbodithioate moiety as potent PKM2 activators.
Li R; Ning X; He J; Lin Z; Su Y; Li R; Yin Y
Bioorg Chem; 2021 Mar; 108():104653. PubMed ID: 33517002
[TBL] [Abstract][Full Text] [Related]
16. Benserazide is a novel inhibitor targeting PKM2 for melanoma treatment.
Zhou Y; Huang Z; Su J; Li J; Zhao S; Wu L; Zhang J; He Y; Zhang G; Tao J; Zhou J; Chen X; Peng C
Int J Cancer; 2020 Jul; 147(1):139-151. PubMed ID: 31652354
[TBL] [Abstract][Full Text] [Related]
17. Pyruvate Kinase M2 Contributes to TLR-Mediated Inflammation and Autoimmunity by Promoting Pyk2 Activation.
Zhang X; Yang Y; Jing L; Zhai W; Zhang H; Ma Q; Li C; Yan F; Cheng D; Zhang J; Ning Z; Shi H; Wang C; Zhao M; Dai J; Li Z; Ming J; Yu M; Wang H; Cheng H; Xiong H; Dong G
Front Immunol; 2021; 12():680068. PubMed ID: 34025679
[TBL] [Abstract][Full Text] [Related]
18. Pyruvate kinase M2 is requisite for Th1 and Th17 differentiation.
Kono M; Maeda K; Stocton-Gavanescu I; Pan W; Umeda M; Katsuyama E; Burbano C; Orite SYK; Vukelic M; Tsokos MG; Yoshida N; Tsokos GC
JCI Insight; 2019 Jun; 4(12):. PubMed ID: 31217348
[TBL] [Abstract][Full Text] [Related]
19. Integrated In Silico-In Vitro Discovery of Lung Cancer-related Tumor Pyruvate Kinase M2 (PKM2) Inhibitors.
Ye X; Sun Y; Xu Y; Chen Z; Lu S
Med Chem; 2016; 12(7):613-620. PubMed ID: 26951145
[TBL] [Abstract][Full Text] [Related]
20. Emerging roles of PKM2 in cell metabolism and cancer progression.
Luo W; Semenza GL
Trends Endocrinol Metab; 2012 Nov; 23(11):560-6. PubMed ID: 22824010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
